Discover the future of mental health care through the eyes of Tony Budden, CEO of PsyLabs, in his thought-provoking feature in Insights Care Magazine. As a pioneer in the development of nature-derived psychedelic compounds like psilocybin and ibogaine, PsyLabs—working in close partnership with Psyence Biomed—is advancing groundbreaking solutions for substance use disorders and other mental health challenges.

In the article, Budden explores the transformative potential of psychedelic-assisted psychotherapy and its ability to reshape how we approach mental health treatment. With a focus on scientific rigor, ethical integrity, and regulatory pathways, he outlines a compelling vision for integrating these therapies into mainstream medicine. This collaboration between PsyLabs and Psyence Biomed marks a significant step toward unlocking the full potential of psychedelics to address deep-rooted mental health conditions.